HomeInsightsStock Comparison

Bal Pharma Ltd vs Bharat Parenterals Ltd Stock Comparison

Bal Pharma Ltd vs Bharat Parenterals Ltd Stock Comparison

Last Updated on: Jul 21, 2025

Key Highlights

  • The Latest Trading Price of Bal Pharma Ltd is ₹ 100.65 as of 21 Jul 11:50.
  • The P/E Ratio of Bal Pharma Ltd changed from 16.8 on March 2021 to 19.5 on March 2024 . This represents a CAGR of 3.80% over 4 yearsThe P/E Ratio of Bharat Parenterals Ltd changed from 3.4 on March 2020 to 45 on March 2024 . This represents a CAGR of 67.63% over 5 years.
  • The Market Cap of Bal Pharma Ltd changed from ₹ 46.13 crore on March 2020 to ₹ 144.21 crore on March 2024 . This represents a CAGR of 25.60% over 5 yearsThe Market Cap of Bharat Parenterals Ltd changed from ₹ 81.25 crore on March 2020 to ₹ 653.08 crore on March 2024 . This represents a CAGR of 51.72% over 5 years.
  • The revenue of Bal Pharma Ltd for the Mar '25 is ₹ 82.96 crore as compare to the Dec '24 revenue of ₹ 73.66 crore. This represent the growth of 12.63% The revenue of Bharat Parenterals Ltd for the Mar '25 is ₹ 105.91 crore as compare to the Dec '24 revenue of ₹ 75.2 crore. This represent the growth of 40.84%.
  • The ebitda of Bal Pharma Ltd for the Mar '25 is ₹ 8.72 crore as compare to the Dec '24 ebitda of ₹ 8.26 crore. This represent the growth of 5.57% The ebitda of Bharat Parenterals Ltd for the Mar '25 is ₹ 4.16 crore as compare to the Dec '24 ebitda of ₹ 6.59 crore. This represent the decline of -36.87%.
  • The net profit of Bal Pharma Ltd changed from ₹ 0.09 crore to ₹ 5.42 crore over 8 quarters. This represents a CAGR of 676.03% The net profit of Bharat Parenterals Ltd changed from ₹ 7.01 crore to ₹ -9.44 crore over 8 quarters. This represents a CAGR of NaN% .
  • The Dividend Payout of Bal Pharma Ltd changed from 16.29 % on March 2021 to 18.46 % on March 2024 . This represents a CAGR of 3.18% over 4 yearsThe Dividend Payout of Bharat Parenterals Ltd changed from 1.78 % on March 2023 to 2.58 % on March 2024 . This represents a CAGR of 20.39% over 2 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Bal Pharma Ltd

  • Bal Pharma Ltd (BPL), a member of the Mcro Laboratories Group, was incorporated as a private limited company in May '87.
  • In Mar.'90, BPL took over a pharmaceutical products manufacturing unit located in Bangalore through the Karnataka State Finance Corporation for a consideration of Rs 25.18 lac following which, BPL commenced manufacturing formulations. BPL manufactures and markets pharmaceutical formulations -- paracetamol, aluminium hydroxide, povidone iodine, alprazolam, gliclazide, griseofulvin, lactobacillus, rifampicin, piroxicam amoxycillin, etc.
  • The company promotes its products through the common sales force of the group but proposes to induct its own soon.
  • It came out with a public issue in Feb.'95 for manufacture of bulk drugs and expansion of pharmaceutical formulations. During 1997-98, the formalities of takeover of the unit from Lakme Limited have been completed and effective from 23rd July, 1997 the unit has become a division of Bal Pharma Limited.

About Bharat Parenterals Ltd

  • Bharat Parenterals Ltd. was incorporated on Sep.'92 in Gujarat and promoted by Ramesh Desai and Bharat Desai.
  • The Company is engaged in the business of manufacturing drugs, pharmaceutical formulations and ayurvedic products at its plant in Baroda.
  • It has set-up a fully integrated and modern plant as per WHO standards at Haripura near Baroda for manufacturing pharmaceutical formulations, life saving drugs, parenterals and antibiotics. In 2016, Varenyam Healthcare Private Limited was incorporated as wholly owned subsidiary company effective 09 July, 2016.
  • Innoxel Lifesciences was incorporated as wholly owned subsidiary company effective 16th October, 2020.
  • Varenyam Biolifesciences got incorporated as wholly owned subsidiary company effective 28th June, 2022.

Bal Pharma Ltd News Hub

News

Board of Bal Pharma recommends final dividend

Bal Pharma announced that the Board of Directors of the Company at its meeting held on 29 ...

Read more

30 May 2025 11:20

News

Bal Pharma to declare Quarterly Results

Bal Pharma will hold a meeting of the Board of Directors of the Company on 29 May 2025. Po...

Read more

17 May 2025 11:42

News

Bal Pharma Ltd leads gainers in 'B' group

Chemcrux Enterprises Ltd, Maral Overseas Ltd, Growington Ventures India Ltd and Orchasp Lt...

Read more

03 Apr 2025 12:15

News

Bal Pharma to hold board meeting

Bal Pharma will hold a meeting of the Board of Directors of the Company on 13 February 202...

Read more

25 Jan 2025 10:17

News

Bal Pharma schedules board meeting

Bal Pharma will hold a meeting of the Board of Directors of the Company on 14 November 202...

Read more

06 Nov 2024 20:13

News

Bal Pharma to convene board meeting

Bal Pharma will hold a meeting of the Board of Directors of the Company on 9 September 202...

Read more

31 Aug 2024 10:27

Bharat Parenterals Ltd News Hub

News

Board of Bharat Parenterals recommends Final Dividend

Bharat Parenterals announced that the Board of Directors of the Company at its meeting hel...

Read more

12 May 2025 17:16

News

Bharat Parenterals to convene board meeting

Bharat Parenterals will hold a meeting of the Board of Directors of the Company on 12 May ...

Read more

06 May 2025 11:30

News

Bharat Parenterals to announce Quarterly Result

Bharat Parenterals will hold a meeting of the Board of Directors of the Company on 3 Febru...

Read more

24 Jan 2025 10:28

News

Bharat Parenterals to announce Quarterly Result

Bharat Parenterals will hold a meeting of the Board of Directors of the Company on 29 Octo...

Read more

21 Oct 2024 10:22

News

Bharat Parenterals announces board meeting date

Bharat Parenterals will hold a meeting of the Board of Directors of the Company on 8 Augus...

Read more

01 Aug 2024 10:54

News

Bharat Parenterals schedules AGM

Bharat Parenterals announced that the Annual General Meeting (AGM) of the company will be ...

Read more

12 Jun 2024 10:01

SWOT Analysis Of Bal Pharma Ltd

Strength

2

S

Weakness

2

W

Opportunity

0

O

Threats

0

T

SWOT Analysis Of Bharat Parenterals Ltd

Strength

1

S

Weakness

0

W

Opportunity

0

O

Threats

0

T

BlinkX Score for Bal Pharma Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Bharat Parenterals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Bal Pharma Ltd and Bharat Parenterals Ltd

Which company has a larger market capitalization, Bal Pharma Ltd or Bharat Parenterals Ltd?

Market cap of Bal Pharma Ltd is 159 Cr while Market cap of Bharat Parenterals Ltd is 1,086 Cr

What are the key factors driving the stock performance of Bal Pharma Ltd and Bharat Parenterals Ltd?

The stock performance of Bal Pharma Ltd and Bharat Parenterals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Bal Pharma Ltd and Bharat Parenterals Ltd?

As of July 21, 2025, the Bal Pharma Ltd stock price is INR ₹100.25. On the other hand, Bharat Parenterals Ltd stock price is INR ₹1576.25.

How do dividend payouts of Bal Pharma Ltd and Bharat Parenterals Ltd compare?

To compare the dividend payouts of Bal Pharma Ltd and Bharat Parenterals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions